About Provisio Medical
Provisio Medical Technologies is a commercial-stage medical device company in San Diego. It makes the SLT IVUS System and the SLT IVUS Support Crossing Catheter in house. Both have 510(k) clearance from the FDA and are available in the United States. On the same hardware, it is building tools for peripheral artery disease that give physicians real-time information during a procedure. Its deep-learning guidance tool, wAIfinder, is at the center of that work.
The company is based at 10815 Rancho Bernardo Road in San Diego. S. Eric Ryan, M.D., founded it in 2014 and is president and chief executive officer. He was previously a senior executive at Volcano Corporation, which Philips Healthcare acquired. Chris Carcerano is vice president and chief development officer. Maybelle Jordan is chief strategy officer, and Kyle Hansen, M.D., is vice president of clinical development. John McCallum chairs the board. Three newer tools, SLT FLOW, SLT Cascade and wAIfinder, are under development and are not available for investigational or commercial use.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 20, 2026 | Oct 22, 2026 | $3,000,000fully sold | 1 | $3.0M | Debt in form of convertible note into shares of a to be designated senior preferred stock of Issuer on terms to be determined.Rule 506(c) | Form D ↗ |
| Jul 27, 2026 | Aug 6, 2026 | $50,000of $10.0M target | 1 | $50,000 | Debt in form of convertible note into shares of a to be designated senior preferred stock of Issuer on terms to be determined.Rule 506(c) | Form D ↗ |
| Total, two offerings | $3,050,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed Provisio Medical
Provisio Medical Technologies makes the SLT IVUS catheter system, which has FDA 510(k) clearance. It is adding blood flow measurement and AI guidance on the same catheter, aimed at peripheral artery disease. Those added tools are still in development. Its chief executive officer, S. Eric Ryan, M.D., previously held a senior clinical and scientific role at Volcano Corporation.
The problem it targets
In Provisio's view, better measurement leads to better outcomes. Its stated aim is to give clinicians real-time insight at the point of treatment. The company wants that insight to reduce reintervention and improve patients' lives. Its mission is to bring precision and confidence to every endovascular procedure.
What the product does
The platform combines four technologies on one catheter. It builds on the cleared SLT IVUS foundation. It adds SLT FLOW for volumetric blood flow, SLT Cascade for computed flow dynamics and wAIfinder for deep-learning guidance. The stated purpose is to size, map and assess success from that single catheter. wAIfinder is built to combine data from the SLT technologies. It aims to guide where and how much to treat across the meter-long peripheral arterial tree. Provisio describes the data from the SLT IVUS catheter as natively AI-ready.
Progress so far
Provisio was founded in 2014 and now describes itself as commercial stage. Its cleared catheter system is available in the United States. The three newer tools are not yet available. The company states that they are not for investigational or commercial use. It adds that its statements about them describe design intent, not claims of safety or effectiveness.
Who backs it
John McCallum chairs the board and has been a director since 2022. In 2010 he founded JAM Capital Partners, a private investment partnership backed by entrepreneurial families and individuals. Michael Chobotov, Ph.D., also a director since 2022, was chief technology officer of Endologix, Inc.
We wrote this summary from public statements by Provisio Medical and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on Provisio Medical's Form D filed Oct 22, 2026.